Shanghai MicroPort Endovascular MedTech Co., Ltd. provided earnings guidance for the year ended 31 December 2022. For the year ended 31 December 2022, the revenue of EV MedTech is expected to be between RMB 855.7907 million and RMB 924.2507 million, representing an increase of between 25% and 35% as compared with 2021. The net profit attributable to the equity owners of EV MedTech is expected to be between RMB 347.4413 million and RMB 379.0268 million, representing an increase of between 10% and 20% as compared with 2021.

The net profit attributable to equity owners of EV MedTech after deducting extraordinary gains or losses is expected to be between RMB 317.3023 million and RMB 346.1479 million, representing an increase of between 10% and 20% as compared with 2021.